Methods for treating Huntington's disease
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
1. A compound, or a form thereof, selected from the group consisting of:
N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine, and
N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine;
wherein a form of the compound is selected from the group consisting of a salt, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
2. A compound salt, or a form thereof, selected from the group consisting of:
N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride, and
N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride;
wherein a form of the compound salt is selected from the group consisting of a clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
3. A method for treating or ameliorating Huntington's Disease in a subject in need thereof comprising administering to the subject an effective amount of the compound, or form thereof, of claim 1 .
4. A method for treating or ameliorating Huntington's Disease in a subject in need thereof comprising administering to the subject an effective amount of the compound salt, or form thereof, of claim 2 .
5. The method of claim 3 , wherein the effective amount of the compound, or form thereof, is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.
6. The method of claim 4 , wherein the effective amount of the compound salt, or form thereof, is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.
7. A pharmaceutical composition comprising the compound of claim 1 , or form thereof, in admixture with one or more pharmaceutically acceptable excipient(s).
8. A pharmaceutical composition comprising the compound salt of claim 2 , or form thereof, in admixture with one or more pharmaceutically acceptable excipient(s).